Salvianolic Acid B Down-regulates Matrix Metalloproteinase-9 Activity and Expression in Tumor Necrosis Factor-α-induced Human Coronary Artery Endothelial Cells
Open Access
- 5 October 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Chinese Medical Journal
- Vol. 128 (19), 2658-2663
- https://doi.org/10.4103/0366-6999.166037
Abstract
Background: Salvianolic acid B (Sal B) is a bioactive water-soluble compound of Salviae miltiorrhizae, a traditional herbal medicine that has been used clinically for the treatment of cardiovascular diseases. This study sought to evaluate the effect of Sal B on matrix metalloproteinase-9 (MMP-9) and on the underlying mechanisms in tumor necrosis factor-α± (TNF-α±)-activated human coronary artery endothelial cells (HCAECs), a cell model of Kawasaki disease.Methods: HCAECs were pretreated with 1–10 αμmol/L of Sal B, and then stimulated by TNF-α± at different time points. The protein expression and activity of MMP-9 were determined by Western blot assay and gelatin zymogram assay, respectively. Nuclear factor-κB (NF-κB) activation was detected with immunofluorescence, electrophoretic mobility shift assay, and Western blot assay. Protein expression levels of mitogen-activated protein kinase (c-Jun N-terminal kinase [JNK], extra-cellular signal-regulated kinase [ERK], and p38) were determined by Western blot assay.Results: After HCAECs were exposed to TNF-α±, 1–10 αμmol/L Sal B significantly inhibited TNF-α±-induced MMP-9 expression and activity. Furthermore, Sal B significantly decreased IκBα± phosphorylation and p65 nuclear translocation in HCAECs stimulated with TNF-α± for 30 min. In addition, Sal B decreased the phosphorylation of JNK and ERK1/2 proteins in cells treated with TNF-α± for 10 min.Conclusions: The data suggested that Sal B suppressed TNF-α±-induced MMP-9 expression and activity by blocking the activation of NF-κB, JNK, and ERK1/2 signaling pathways.Keywords
This publication has 29 references indexed in Scilit:
- Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte functionJCI Insight, 2011
- Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective StudyThe Journal of Pediatrics, 2011
- Tumor necrosis factor-α induces MMP-9 expression via p42/p44 MAPK, JNK, and nuclear factor-κB in A549 cellsToxicology and Applied Pharmacology, 2008
- Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki diseaseEuropean Journal of Pediatrics, 2008
- Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusionPharmacology & Therapeutics, 2008
- EPIDEMIOLOGIC STUDY ON KAWASAKI DISEASE IN BEIJING FROM 2000 THROUGH 2004The Pediatric Infectious Disease Journal, 2007
- Salvianolic acid B attenuates cyclooxygenase‐2 expression in vitro in LPS‐treated human aortic smooth muscle cells and in vivo in the apolipoprotein‐E‐deficient mouse aortaJournal of Cellular Biochemistry, 2006
- Diagnosis, Treatment, and Long-Term Management of Kawasaki DiseaseCirculation, 2004
- ERK1/2 mediates TNF‐α‐induced matrix metalloproteinase‐9 expression in human vascular smooth muscle cells via the regulation of NF‐κB and AP‐1: Involvement of the ras dependent pathwayJournal of Cellular Physiology, 2003
- Salvianolic acid B attenuates VCAM‐1 and ICAM‐1 expression in TNF‐α‐treated human aortic endothelial cellsJournal of Cellular Biochemistry, 2001